1. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W et al: The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68 Suppl 2:ii1-44.
2. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J: Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003, 23(2):61-66.
3. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M et al: The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68(6):777-783.
4. Toussirot E, Wendling D: Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options. Drugs Aging 2005, 22(6):451-469.
5. Endo Y, Fujikawa K, Koga T, Mizokami A, Mine M, Tsukada T, Uetani M, Kawakami A: Characteristics of late-onset spondyloarthritis in Japan: A retrospective cohort study. Medicine (Baltimore) 2019, 98(7):e14431.
6. Skare TL, Leite N, Bortoluzzo AB, Gonçalves CR, da Silva JA, Ximenes AC, Bértolo MB, Ribeiro SL, Keiserman M, Menin R et al: Effect of age at disease onset in the clinical profile of spondyloarthritis: a study of 1424 Brazilian patients. Clin Exp Rheumatol 2012, 30(3):351-357.
7. Karaarslan A, Yilmaz H, Aycan H, Orman M, Kobak S: Demographic, clinical, and laboratory features of Turkish patients with late onset ankylosing spondylitis. Bosn J Basic Med Sci 2015, 15(3):64-67.
8. Chen HA, Chen CH, Liao HT, Lin YJ, Chen PC, Chen WS, Chien CC, Chou CT: Clinical, functional, and radiographic differences among juvenile-onset, adult-onset, and late-onset ankylosing spondylitis. J Rheumatol 2012, 39(5):1013-1018.
9. Montilla C, Del Pino-Montes J, Collantes-Estevez E, Font P, Zarco P, Mulero J, Gratacós J, Rodríguez C, Juanola X, Fernández-Sueiro JL et al: Clinical features of late-onset ankylosing spondylitis: comparison with early-onset disease. J Rheumatol 2012, 39(5):1008-1012.
10. Toussirot É: Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations. Drugs Aging 2015, 32(7):515-524.
11. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M et al: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017, 76(6):978-991.
12. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A et al: 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019, 71(10):1599-1613.
13. Kim SK, Choe JY, Lee SS, Shin K: Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: Data from the Korean College of Rheumatology BIOlogics (KOBIO) registry. Mod Rheumatol 2017, 27(5):855-861.
14. van der Linden S, Valkenburg HA, Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27(4):361-368.
15. Toussirot E: Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies. Drugs Aging 2010, 27(7):523-531.
16. Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D: Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70(1):47-53.
17. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44(8):1876-1886.
18. Micheroli R, Tellenbach C, Scherer A, Bürki K, Niederman K, Nissen MJ, Zufferey P, Exer P, Möller B, Kyburz D et al: Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. Ann Rheum Dis 2020, 79(9):1203-1209.
19. Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ: Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015, 1(1):e000017.
20. Lahaye C, Tatar Z, Dubost JJ, Soubrier M: Overview of biologic treatments in the elderly. Joint Bone Spine 2015, 82(3):154-160.
21. Baraliakos X, van den Berg R, Braun J, van der Heijde D: Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012, 51(8):1378-1387.
22. Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P et al: Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013, 382(9906):1705-1713.
23. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M et al: Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med 2015, 373(26):2534-2548.
24. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P: Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006, 65(3):379-384.
25. Fleischmann R, Iqbal I: Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. Drugs Aging 2007, 24(3):239-254.
26. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF: Survival and safety of treatment with infliximab in the elderly population. Rheumatology (Oxford) 2005, 44(5):695-696.
27. Maillard H, Ornetti P, Grimault L, Ramon JF, Ducamp SM, Saidani T, Tavernier C, Maillefert JF: Severe pyogenic infections in patients taking infliximab: a regional cohort study. Joint Bone Spine 2005, 72(4):330-334.
28. Arends S, van der Veer E, Kallenberg CG, Brouwer E, Spoorenberg A: Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 2012, 24(3):290-298.
29. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE: Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky. Curr Rheumatol Rep 2018, 20(6):35.
30. Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th AJTL, Kallenberg CG, Spoorenberg A: Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011, 13(3):R94.
31. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML: Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69(11):2002-2008.
32. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P: Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010, 62(10):1362-1369.
33. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitz-Bortz E, Flörecke M, Bollow M et al: Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken) 2012, 64(9):1415-1422.